EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Neoadjuvant Immunotherapy: A Promising New Standard of Care

Emma Boydell, Jose L Sandoval, Olivier Michielin, Michel Obeid, Alfredo Addeo iD, Alex Friedlaender

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms241411849 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Emma Boydell und 5 weiteren Autor:innen. Beteiligte Einrichtung: University Hospital of Geneva, 1205 Geneva, Switzerland. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Triple Negative Breast Neoplasms. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 107 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Neoadjuvant immunotherapy has emerged as a promising approach in the treatment of various malignancies, with preclinical studies showing improved immune responses in the preoperative setting. FDA-approved neoadjuvant-immunotherapy-based approaches include triple-negative breast cancer and early non-small cell lung cancer on the basis of improvement in pathological response and event free survival. Nevertheless, current trials have only shown benefits in a fraction of patients. It is therefore crucial to identify predictive biomarkers to improve patient selection for such approaches. This review aims to provide an overview of potential biomarkers of neoadjuvant immunotherapy in early triple-negative breast cancer, bladder cancer, melanoma, non-small cell lung cancer, colorectal cancer and gastric cancer. By the extrapolation of the metastatic setting, we explore known predictive biomarkers, i.e., PD-L1, mismatch repair deficiency and tumour mutational burden, as well as potential early-disease-specific biomarkers. We also discuss the challenges of identifying reliable biomarkers and the need for standardized protocols and guidelines for their validation and clinical implementation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsTriple Negative Breast NeoplasmsHumansNeoadjuvant TherapyStandard of CareBiomarkers, TumorImmunotherapyB7-H1 Antigen

Stichwörter der Autor:innen

NSCLCgastric cancerimmunotherapymelanomaneoadjuvantpredictive biomarkersurothelial carcinoma

Substanzen

Biomarkers, TumorB7-H1 Antigen

Autor:innen und Institutionen

  • University Hospital of Geneva, 1205 Geneva, Switzerland.
  • University Hospital of Lausanne, 1005 Lausanne, Switzerland.
  • Clinique Générale Beaulieu, 1206 Geneva, Switzerland.

ORCID-Profile: Alfredo Addeo

Zitieren

APA

Boydell, E., Sandoval, J. L., Michielin, O., Obeid, M., Addeo, A., & Friedlaender, A. (2023). Neoadjuvant Immunotherapy: A Promising New Standard of Care. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms241411849

Vancouver

Boydell E, Sandoval JL, Michielin O, Obeid M, Addeo A, Friedlaender A. Neoadjuvant Immunotherapy: A Promising New Standard of Care. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms241411849

BibTeX
@article{Boydell2023,
  author = {Boydell, Emma and Sandoval, Jose L and Michielin, Olivier and Obeid, Michel and Addeo, Alfredo and Friedlaender, Alex},
  title = {Neoadjuvant Immunotherapy: A Promising New Standard of Care},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms241411849}
}
Kostenlos starten →